Protein / target
Fusion glycoprotein F0
Protein at a glance
Biological role
Entry receptor-mediated virion attachment to host cell
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Inactive precursor that is cleaved at two sites by a furin-like protease to give rise to the mature F1 and F2 fusion glycoproteins
Subcellular location
Domains and Gene Ontology detail (8)Hide
Gene Ontology
- Chost cell Golgi membrane
- Chost cell plasma membrane
- Cviral envelope
- Cvirion membrane
- Pentry receptor-mediated virion attachment to host cell
- Pfusion of virus membrane with host plasma membrane
- Psymbiont entry into host cell
- Psymbiont-mediated induction of syncytium formation
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Fusion glycoprotein F0 inhibitor
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Regulatory approval
Approval: Enflonsia (EMA)
- New publicationA Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants.
- New publicationDevelopment of High-Titer Antidrug Antibodies in a Phase 1b/2a Infant Clesrovimab Trial Are Associated With RSV Exposure Beyond Day 150.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.